Background: Eritoran tetrasodium (E5564), a structural analogue of the lipid A portion of endotoxin (lipopolysaccharide or LPS), is an antagonist of LPS and other Toll-like receptor 4 (TLR4) ligands. Eritoran tetrasodium quantitatively blocks LPS response in vivo in animal and human endotoxemia models and demonstrates a long pharmacokinetic half-life, but a short pharmacodynamic half-life. The objective of this study was to assess the safety, and pharmacokinetic and pharmacodynamic profile of E5564 infused twice-daily at three target steady-state plasma levels of approximately 1, 3 and 10 µg/ml in healthy volunteers. Results: Loading and maintenance doses of up to 77 mg over 3 days in females and 105 mg over 6 days in males were safe and well-tolerated except for self-limiting phlebitis at the drug infusion site. Plasma levels reached steady state by 24 h. The C max , C min , and C ss , AUC 0-∞ were dose proportional and gender independent. Pharmacodynamic activity measured by an ex vivo LPS challenge assay, demonstrated dose-dependence for both E5564 and LPS and plasma levels of~3 µg/ml E5564 or greater blocked up to 1 ng/ml LPS. Conclusions: Every 12-h dosing of E5564 can replace continuous infusion, while maintaining uninterrupted blocking of high-dose LPS.
INTRODUCTION
Eritoran tetrasodium (E5564) is a second-generation synthetic lipid A analogue 1,2 that has been designed to antagonize the effects of endotoxin from Gram-negative bacteria 3, 4 by interacting with Toll-like receptor 4 (TLR4), 4 the cell-surface receptor for lipopolysaccharide (LPS). 5, 6 Clinically, eritoran tetrasodium is being investi-gated for the treatment of severe sepsis and other endotoxin-mediated indications. Results from in vitro studies have found eritoran tetrasodium to be a highly active antagonist of LPS-mediated activation of responsive cells, but that low concentrations of eritoran tetrasodium have a relatively short pharmacodynamic half-life in blood or plasma that is observable in the absence of clearance or measurable metabolism. 4 In vivo studies of short infusions into human volunteers 7 and animal model studies 8 further support this observation by demonstrating that low-dose eritoran tetrasodium is extremely active when co-administered with LPS, but activity decreases shortly after ending infusion into humans and dogs. This occurs even though eritoran tetrasodium has a plasma elimination half-life of 40-50 h, 7, 8 likely due to binding and inactivation by plasma lipoproteins. 9 Studies by Rose and co-workers 10 have supported the importance of plasma lipoprotein binding in influencing the long-term effectiveness of E5531, a similar lipid A analogue. In these in vitro studies, E5531 lost activity when bound to high-density lipoprotein (HDL), while little or no loss in activity occurred upon association with low-density lipoprotein (LDL) or very-low-density lipoprotein (VLDL). 10 Similar studies with eritoran tetrasodium have yielded results suggesting that eritoran tetrasodium also was inactivated, but more slowly than E5531, 4 indicating that it may be a better therapeutic entity. To overcome loss in activity, continuous infusion of eritoran tetrasodium was evaluated 9, 11 and long-term activity was established, albeit at greatly reduced potency compared to that of freshly-infused drug. 7 But losses in pharmacodynamic activity roughly paralleled losses in plasma levels. Surprisingly, activity is also retained for more than 72 h after ending infusion. These results indicated that extended pharmacodynamic activity may be established in dosing strategies other than continuous infusion. The dosing regimens in this study were designed to determine if target plasma levels of 1, 3, and 10 µg/ml of eritoran tetrasodium could inhibit 0.05, 1, and 10 ng/ml of LPS, respectively, in an ex vivo assay.
Human in vivo studies employing endotoxin administration to normal volunteers supply important direct information on antagonistic activity. However, these studies are limited by an inability to perform multiple or high-dose endotoxin administrations, such as might occur during severe sepsis and septic shock. For this reason, we have applied a model of ex vivo testing to determine how effectively eritoran tetrasodium blocks endotoxin challenge doses of up to 10 ng/ml throughout and following the period of test drug administration, with particular focus on C min or pharmacokinetic 'troughs' that occur prior to each dose administration.
The pharmacodynamic activity of eritoran tetrasodium was determined by use of an ex vivo assay that measures the induction of tumor necrosis factor (TNF)-α by LPS added to whole blood samples drawn from placebo and eritoran tetrasodium-treated subjects. After 3-h incubation with 0, 1, or 10 ng/ml LPS, plasma from these samples was tested for cellular activation by analyzing for concentrations of TNF-α. LPS-induced TNFα was measured in blood samples taken from the volunteers prior to drug administration to serve as controls for baseline LPS response.
Results indicated that use of a 4-h and 2-h loading dose followed by 2-h maintenance infusions every 12 h were safe and well-tolerated, except for induction of injection site pain and inflammation (phlebitis). Phlebitis was the only adverse event that was related to eritoran tetrasodium, as incidence and severity were proportional to dose level administered. eritoran tetrasodium C max , C min , C ss and AUC 0-∞ were dose proportional and total exposure of eritoran tetrasodium (AUC 0-∞ ) was~30% higher in females than in males, probably due to lower body weights.
Antagonistic activity measured by our ex vivo assay, indicates that plasma levels of~3 µg/ml continuously protects against 1 ng/ml LPS in blood.
PATIENTS AND METHODS

Reagents
Eritoran tetrasodium was synthesized at Eisai Research Institute Chemical Development and was formulated as described elsewhere. 12 LPS (from Escherichia coli O111:B4) from List Biological Laboratories as well as other reagents have been described previously. 10, 13 
Origin of samples and study design
This study was performed at the Clinical Research Center, New Orleans, LA, USA as a double-blind, placebo-controlled, safety and tolerability study of eritoran tetrasodium, administered twice daily by intravenous infusions over 3 days or 6 days in healthy male and female volunteers (five treated and two placebo males per group, three treated/one placebo female per group). Informed consent was obtained from all subjects, and human experimentation guidelines of the US Department of Health and Human Services were followed in the conduct of this clinical research. Volunteers were kept at the study site at least 168 h after completing the last drug infusion. Concomitant medications were not allowed during or within 48 h of study. Dosages of 11, 33, or 77 mg (105 mg in high-dose males) were intravenously administered over 3 days (6 days in high-dose males). Dosing regimens are described in Table 1 .
Dose level III (females)
7 mg/h × 4 h (loading dose 1) at T 0 , 7 mg/h × 2 h (loading dose 2) at 12 h, 3.5 mg/h × 2 h (maintenance doses) every 12 h until T 74 h (7 doses).
Dose level III (males only) 7 mg/h × 4 h (loading
dose 1) at T 0 , 7 mg/h × 2 h (loading dose 2) at 12 h, 3.5 mg/h × 2 h (maintenance doses) every 12 h until T 122 h (11 doses).
All 33 subjects enrolled into this study completed the study and were discharged as scheduled. Except for samples from one subject who missed a pharmacokinetic/ex vivo sampling at 264 h and vital signs at 252, 264, 276 h, there were no drop-outs or missing data.
Pharmacokinetics
Blood samples from healthy volunteers dosed with each dose level were assayed for eritoran tetrasodium plasma content. Plasma samples (EDTA) were collected up to 240 h (males and females) or 288 h (high-dose males only), and assayed using a validated liquid chromatography/mass spectrometry method. 7 Pharmacokinetic parameters for eritoran tetrasodium were estimated using non-compartmental methods. Samples obtained from placebo subjects were all below quantification limit (< 5 ng/ml or 50 ng/ml when diluted) with the exception of subject 002. Eritoran tetrasodium was detected (67.3-160.8 ng/ml) from 36 h to 96 hr. The reason for this finding was not clear, but was likely due to misadministration of a small amount of active drug (up to 7 mg) rather than placebo/5% dextrose in water during the 36-38 h infusion period.
Pharmacodynamic analysis of eritoran tetrasodium activity in whole blood
Ex vivo activity was assessed as previously described 7 and was procedurally similar to those described for in vitro analysis of eritoran tetrasodium activity. 10 Briefly, samples of heparinized whole blood (0.40 ml) were dispensed to a 48-well cell culture cluster plate in triplicate, 50 µl of phosphate-buffered saline (PBS) were added, then 50 µl of LPS in 5% dextrose in water or 5% dextrose in water alone was added to generate samples containing 10, 1, 0.05 or 0 ng/ml LPS (final concentration). After 3-h incubation at 37ºC/5% CO 2 with gentle shaking (Belco plate shaker), all samples were reduced to plasma by centrifugation (900 g) using an ELISA plate centrifuge. Samples (100 µl) were transferred into wells of duplicate 96-well microtiter plates, quick-frozen, and stored at -80ºC until assayed by ELISA using kits by Endogen (Cat #EH2TNFA; limit of sensitivity of < 5.0 pg/ml TNF-α) and Pierce/Endogen (Cat #EH3TNFA; limit of sensitivity of < 2.0 pg/ml TNF-α). For TNF-α response, each subject served as their own control using the T -1 response (response to endotoxin prior to receiving any drug or placebo) as baseline. For each subject, the percentage response time (mean and SD) was calculated from: % resonse = (response at time T/response at time T -1 ) × 100 Eq. 1
Statistical analysis
Drug assignment was not unblinded until the results database was locked. All data are presented by dose group as mean ± SD or SEM. Safety data were evaluated, when appropriate, by nonparametric procedures and descriptive summary statistics, whereas different dose groups were analyzed by appropriate parametric and non-parametric statistical procedures for a multiple sample design. All statistical tests are two-sided and declared significant at α < 0.05. Relationships between pharmacodynamic and pharmacokinetic parameters were explored.
Protocol violators who did not complete drug infusions (one male in the high-dose group and one female in the high-dose group) and subjects who received placebo were excluded from the pharmacokinetic analysis. All subjects were included in the pharmacodynamic analysis.
PK/PD of eritoran tetrasodium during and after intermittent infusion 385 Plasma distribution of eritoran tetrasodium was compared between different plasma groups by analysis of variance (INSTAT, v.2.0, GraphPad Software). Critical differences were assessed by Newman-Keuls post hoc tests and considered significant if P < 0.05.
RESULTS
Safety
Subjects were observed during the infusion period and for up to 166 h (high dose) or 216 h following infusion. No LPS-like agonistic activity was associated with eritoran tetrasodium administration as evidenced by change in vital signs or presence of signs or symptoms usually associated with endotoxemia (e.g. fever, chills, myalgia, leukocytosis). 12 Table 2 lists adverse events by frequency in each dose level. Injection site pain and inflammation was the most common adverse event (5 incidences of pain, 6 of local inflammation) and were the only adverse events to show dose-response and rated 'probably related' to the study medication by the investigator. Injection-site pain was mild in all cases, and severity of inflammation was moderate (two cases in the high-dose groups) and mild in the other cases. These instances resolved after discontinuing infusion of study drug from the injection site. All other reported treatment-emergent signs and symptoms were mild in severity.
Two subjects (dose level II) experienced vasodilation (flushing) and two in the high-dose group experienced conjunctivitis. Three subjects administered eritoran tetrasodium experienced mild elevations in liver function tests (< 2× ULN). One subject was in the low-dose group and two in dose level II (none in the high-dose group). While we cannot rule out the possibility that these changes were not eritoran tetrasodium-induced, there was no clear dose-dependence for eritoran tetrasodium.
There are no apparent differences in the safety of eritoran tetrasodium between males and females.
Pharmacokinetics
Mean plasma concentration-versus-time curves of eritoran tetrasodium for male and female subjects in each dose group are presented in Figures 1 and 2 , respectively. Pharmacokinetic parameters are summarized in Table 3 . Plasma levels of eritoran tetrasodium increased rapidly after the first loading dose (0-4 h), and decreased slowly after the last maintenance dose (72 h or 120 h). Elimination half-life in humans (~35-55 h) was long compared to the dosing interval (12 h); thus, accumulation was large (mean accumulation index~5), and the fraction remaining at the end of dosing interval (trough) was about 80% for all the dosed groups. Fluctuations in plasma levels of eritoran tetrasodium between 24 h (first maintenance dose) and the last maintenance dose were Table 2 . Incidence of treatment-emergent signs and symptoms (TESS) that occurred more frequently in subjects administered eritoran tetrasodium than placebo TESS -Treatment-emergent Placebo Dose level I Dose level II Dose level III Fisher's exact signs and symptoms (n = 9) (n = 8) (n = 8) (n = 8) P-value low-, mid-, and high-dose groups, respectively. The mean plasma concentrations at steady-state (C ss ) of eritoran tetrasodium were 1.0, 2.6 and 9.7 µg/ml (males), and 1.3, 3.9 and 11.0 µg/ml (females) for low-, mid-, and high-dose groups, respectively. The C max , C min , and C ss values increased proportionally with an increase in dose for both male and female subjects. There was a doseresponse effect on C max , C min , and C ss (P < 0.0001). However, there was a gender difference in these parameters (P < 0.05). The AUC 0-∞ values were 132, 343 and 1749 µg . h/ml (males), and 174, 513 and 1454 µg . h/ml (females) for low-, mid-, and high-dose groups, respectively. The AUC 0-∞ increased with dose (P < 0.0001), and there was a gender difference (P < 0.05). This could be due to the fact that the mean body weight of females was significantly lower than that of males. Therefore, females received more drug on a per kilogram body weight basis. This was also noticed in the total clearance (CL). The CL was significantly slower in females when CL was expressed as ml/h; however, this gender differ-ence disappeared when CL was expressed as ml/h/kg. The CL values were 1.36, 1.29 and 0.907 ml/h/kg (males), and 1.02, 1.13 and 0.755 ml/h/kg (females) for low-, mid-, and high-dose groups, respectively, indicating that eritoran tetrasodium was cleared from the body slowly. The clearance decreased with dose in males (P = 0.0127), but not in females. The volumes of distribution (V) were approximately 57-67 ml/kg for both genders ( Table 3 ). The small volume of distribution indicates that eritoran tetrasodium was not extensively distributed into tissues. The elimination half-lives (t 1/2 ) ranged from 26.9-54.7 h (males) and 31.0-56.0 h (females). The elimination half-life was independent of dose and gender.
Ex vivo pharmacodynamic analysis of eritoran tetrasodium
Examination of the activity of infused eritoran tetrasodium was tested by exposing blood samples drawn pre-and postdosing and 'challenging' these samples with 0, 0.05, 1, or 10 ng/ml LPS, and determining resultant TNF-α levels.
388 Rossignol, Wong, Noveck, Lynn Pre-dose (control or T -1 ) samples of blood were drawn approximately 1 h prior to beginning eritoran tetrasodium infusion. Results indicated that blood from each of the subjects drawn at T -1 generated levels of 895 ± 623 pg/ml TNF-α when 0.05 ng/ml LPS was used as agonist, 3124 ± 1555 pg/ml TNF-α when 1 ng/ml LPS was used as agonist and 3983 ± 1802 pg/ml TNF-α when 10 ng/ml LPS was used as agonist. These responses are comparable to those found in previous studies. 7, 9 Interestingly, response of whole blood from females was approximately 50% of that in males: 402 ± 211 pg/ml TNF-α with 0.05 ng/ml LPS, 1641 ± 733 pg/ml TNF-α with 1 ng/ml LPS and 2372 ± 902 pg/ml TNF-α with 10 ng/ml LPS (P < 0.0026 for gender differences in responses to each of the three LPS concentrations).
Induction of TNF-α by LPS stimulation in ex vivo blood samples from placebo-administered subjects
As shown in Figure 3 , blood from volunteers infused with placebo responded vigorously to LPS throughout the analysis period. Compared to mean response values at T -1 , some variability was observed in the mean response over the test period. Response was 83 ± 28% of T -1 response for 1 ng/ml LPS in males and 100 ± 23% of T -1 response for 1 ng/ml LPS in females. This indicates that response to LPS is robust throughout the study period, but varies between 60% and 120% of control.
Inhibition of response to low-dose LPS in subjects infused with eritoran tetrasodium
As shown in Figure 4 , inhibitory activity of eritoran tetrasodium against the low dose of 0.05 ng/ml of LPS is nearly complete (> 95%) at all doses throughout the dosing period, including the C min at 12 h that occurs just prior to the second loading dose. Return of LPS response did not occur throughout the study period (up to 166 h post-infusion) in the dose level III group. In contrast, return of LPS response (26% response) was found 72 h after low-dose eritoran tetrasodium treatment was ended, and at dose level II, 15% response was measurable at 142 h after treatment. Return of response in females was roughly similar to that in males, but the high-dose females (dose level III) demonstrated a modest return of response (4.2%) at 166 h following treatment.
Inhibition of response to 1 ng/ml LPS in eritoran tetrasodium-administered subjects
Results for antagonism of 1 ng/ml LPS (Fig. 5 ) demonstrate that, as above, inhibition of response is dosedependent for eritoran tetrasodium. Antagonism by the highest dose of eritoran tetrasodium (dose level III) was greater than 96% during treatment, whereas inhibition by dose level II was 95-97% and inhibition by low-dose eritoran tetrasodium (dose level I) was < 80% throughout treatment. The higher LPS challenge dose use in this study also revealed a loss of activity during the C min at 12 h (prior to the second loading dose). Only the highest eritoran tetrasodium dose blocked LPS activity during this period.
Inhibition of response to 10 ng/ml LPS in eritoran tetrasodium-administered subjects
Results for antagonism of 10 ng/ml LPS (Fig. 6 ) again demonstrate that inhibition of response is dose-dependent PK/PD of eritoran tetrasodium during and after intermittent infusion 389 Fig. 3 . Induction of TNF-α ex vivo in blood taken from placebo-treated subjects. Blood samples from six male (A) and three female subjects (B) treated with placebo were taken at the times indicated on the x-axis and were stimulated in triplicate with 0.05 ng/ml LPS (inverted filled triangles), 1 ng/ml LPS (filled squares), or 10 ng/ml LPS (filled circles) at 37ºC for 3 h and assayed for release of TNF-α as described in the Patients and Methods. Note that data for the 264 h and 288 h time points are derived from only two individuals. Percentage of T -1 response (y-axis) is calculated from the TNF-α release measured in blood taken approximately 1 h before drug administration. All values are mean ± SE.
for LPS as well as eritoran tetrasodium. Antagonism of this very high challenge dose is inhibited~97% in males by the highest dose level of eritoran tetrasodium (~90% in females). Lower doses of eritoran tetrasodium inhibited 65-70% in males and females (dose level II), and averaged only~50% in males (60-70% in females) through the dosing period of dose level I.
Loss of activity is particularly striking for the 12-h C min at the two lower doses in males and females (< 40% inhibition), but antagonistic activity is still apparent at the high-dose eritoran tetrasodium (inhibition onlỹ 50-75%). Even at high dose, there is no lag in return of LPS response, indicating that protection against this very high dose of LPS does not persist past the dosing period in males. Inhibition of response in females is never complete, thus no lag can be estimated.
Correlation of pharmacokinetics to pharmacodynamics
As eritoran tetrasodium plasma levels decline, as in the post-dosing elimination phase, eritoran tetrasodium activity also declines. This activity can be studied as inhibitory activity (mean percentage inhibition) as a function of concentration of eritoran tetrasodium in plasma. This analysis indicates that plasma levels of eritoran tetrasodium correlate to activity, and that no obvi-390 Rossignol, Wong, Noveck, Lynn Fig. 4 . Mean inhibition of low-dose LPS-induced TNF-α release in ex vivo blood samples from eritoran tetrasodium-infused volunteers. Blood samples from five male volunteers (A) or three female volunteers (B) each infused with eritoran tetrasodium dose level I (filled circles), dose level II (filled squares), or dose level III (filled inverted triangles), were drawn prior to beginning infusion (-1 h) or at the times after starting dosing as indicated on the x-axis. End of last dose (74 h for all dose levels in females and dose levels I and II in males, and 122 h for dose level III males) is indicated by the arrows. All samples were incubated in triplicate with 0.05 ng/ml LPS at 37ºC for 3 h, and the plasma assayed for release of TNF-α as described in Patients and Methods. All values are mean ± SE. , dose level II (filled squares), or dose level III (filled inverted triangles), were drawn prior to beginning infusion (-1 h) or at the times after starting dosing as indicated on the x-axis. End of last dose (74 h for all dose levels in females and dose levels I and II in males, and 122 h for dose level III males) is indicated by the arrows. All samples were incubated in triplicate with 1 ng/ml LPS at 37ºC for 3 h, and the plasma assayed for release of TNF-α as described in Patients and Methods. All values are mean ± SE. ous differences are apparent between response in blood from males and females. An example of this analysis using the LPS challenge dose of 1 ng/ml is displayed in Figure 6 . When 1 ng/ml LPS is used as agonist, the minimum concentration of eritoran tetrasodium required to inhibit by 100% can be estimated to be approximately~3 µg/ml. Similar analyses performed for LPS challenge concentrations of 0.05 ng/ml and 10 ng/ml indicated that plasma concentrations of~1 µg/ml and~12 µg/ml eritoran tetrasodium were required to provide 100% inhibition, respectively ( Table 4 ).
Duration of action of eritoran tetrasodium
Analysis of antagonistic activity after ending dosing can be estimated by studying the lag in return of LPS response. As can be seen in Figures 4-6 , and summarized in Table 5 , the duration of this lag is dependent on the amount of drug infused as well as the amount of LPS used as challenge. However, we can summarize the results as follows.
A plasma concentration of~1.2 µg/ml eritoran tetrasodium completely blocks activation by 0.05 ng/ml LPS for > 22 h post dosing. Eritoran tetrasodium levels of > 3 µg/ml eritoran tetrasodium (mid-and low-dose groups) completely blocked 1 ng/ml LPS for > 22 h after ending dosing. Inhibition of 10 ng/ml LPS was incomplete immediately after ending dosing with all dose levels of eritoran tetrasodium.
PK/PD of eritoran tetrasodium during and after intermittent infusion 391 Estimation of IC 50 and IC 100 was by average of the values obtained from interpolation from the best-fit line for males and females as shown for 1 ng/ml LPS challenge in Figure 7 . 
DISCUSSION
Because eritoran tetrasodium inactivates rapidly once bound to HDL and remains in the circulation, measurement of pharmacokinetics alone is not sufficient for accurate prediction of eritoran tetrasodium dosing. While continuous dosing may provide the most effective means of administering eritoran tetrasodium, it is impractical to provide long-term continuous infusion to an out-patient, or dedicate a line for infusion of a single drug in the intensive care unit. To this end, this study aimed at attaining continuous protection (LPS antagonism) with twice daily dosing. To determine if antagonistic activity was sufficient and continuous, activity was measured in an ex vivo assay by taking blood samples from dosed subjects and testing it for its ability to respond to LPS. In placebo-treated subjects, response to LPS is robust throughout the study period, but varies between 60-120% of control, likely reflecting variation in preparations of endotoxin as well as diurnal variation of response due to endogenous cortisol levels. 14 During and after infusion of eritoran tetrasodium, potent LPS antagonistic activity is measurable, even when relatively high concentrations of LPS are used as agonist. In addition, antagonistic activity of eritoran tetrasodium appears to be by a competitive mechanism as activity is dose-dependent for concentration of agonist (LPS) as well as concentration of antagonist (eritoran tetrasodium). This physiological observation is supported by the in vitro report that E5531 (a close structural analogue of eritoran tetrasodium) as well as eritoran tetrasodium can competitively inhibit LPS activation of TLR4 through its binding to MD-2. 15, 16 Results from assays performed on subjects during peak drug activity (generally while drug was infused) indicated that 100% inhibition could be attained in all subjects, as activity diminished; however, response to endotoxin between individuals was variable, likely reflecting different levels of active drug from subjects possessing varying lipoprotein levels and ratios of HDL to other lipoproteins. Ex vivo results can be compared to those found in vivo when endotoxin was administered to subjects receiving eritoran tetrasodium; 11, 12 however, those estimates of activity are obviously limited by the amount of endotoxin that can be administered to humans (up to 4 ng/kg) which is estimated to provide a maximum plasma endotoxin concentration of about 50 pg/ml.
Safety of eritoran tetrasodium was demonstrated for doses up to 77 mg in females administered every 12 h over 3 days and up to 105 mg over 6 days in males. Except for the occurrence of injection site pain and inflammation, Eritoran tetrasodium appears generally safe and well-tolerated when administered by this regimen. The C max , C min , and C ss increased proportionally with increasing dose in both females and males (see Table 3 ). The AUC 0-∞ appeared to be dose-proportional in females (11-77 mg) and males (11-33 mg) . The total exposure of eritoran tetrasodium, expressed as AUC 0-∞ , was~30% higher in females than in males. This could be due to females receiving more drug than males on a body-weight basis. However, this increase in exposure was not associated with additional or more severe adverse events. The more than dose proportional increase in AUC 0-∞ from 33 mg to 105 mg in males was likely due to a decrease in total clearance observed in the high-dose group. There were no gender differences in clearance and volume of distribution after values were normalized by body weight.
Results obtained in this study for total clearance and volume of distribution were similar to those determined from administration of doses up to 252 mg over 72 h -CL~0.9 ml/h/kg and V~50 ml/kg. 9 In comparison to continuous infusion, the design for this every 12 h dosing scheme was modeled to achieve steady-state plasma levels by 24 h for all the dose groups Fig. 7 . Correlation of inhibition of LPS-induced TNF-α release to plasma eritoran tetrasodium concentration (correlation of pharmacokinetics to pharmacodynamics). Results (mean percentage inhibition) of ex vivo response to 1 ng/ml LPS in blood from males (filled circles) and females (filled squares) during the post-dosing elimination phase was plotted as a function of mean eritoran tetrasodium concentration measured from samples obtained at the same time points as the respective ex vivo assay. Results from all dose levels were pooled for this analysis. Results are from blood samples incubated in triplicate with 1 ng/ml LPS for 3 h at 37ºC, and the plasma assayed for release of TNF-α as described in the caption to Figure 4 . The best-fit logarithmic line presented in the figure has a correlation coefficient (R) of 0.94585 for males and 0.85713 for females. Because this analysis is focused on results at limiting drug concentration, only data points on the dose-response portion of the curve for each individual were used. Data corresponding to all eritoran tetrasodium plasma concentrations above the first point where ex vivo response is > 99% and < 1% inhibited are excluded from this analysis, as this would include a great number of points (drug concentrations in excess) that demonstrate 100% or 0% inhibition. with plasma eritoran tetrasodium levels high enough to provide extended inhibition of endotoxin response between doses. Twice-a-day dosing was anticipated to do this without excessively increasing plasma concentrations and promoting extended endotoxin insensitivity.
Relevance of the LPS challenge doses for this study was carefully considered, as the amount of endotoxin that is present and active in blood during severe sepsis has been difficult to ascertain. Response to a single dose of 4 ng/kg LPS during in vivo endotoxin challenge studies is significant and reproducible and we can estimate that the equilibrium plasma concentration of LPS after this bolus challenge could be as high as 0.05 ng/ml (a 70-kg person has approximately six litres of blood). Furthermore, concentrations of LPS in septic patients are generally found to be at, or below, 1 ng/ml, but extreme values as high as 10 ng/ml have also been reported. 17 Lipopolysaccharide is known to both rapidly clear from circulation, while at the same time, can associate with plasma lipoproteins and become inactive. 18, 19 For this reason, estimation of concentrations of active endotoxin in patients has been impossible to determine. However, it is likely that range of concentrations of LPS tested in vitro in this study represent all or most of the possible levels of agonist pathophysiological challenge levels, as these levels are generated by instantaneous addition and are clearly not the product of long, slow accumulation accompanied by concomitant inactivation that likely occur in vivo. Thus, inhibition of 1 ng/ml LPS ex vivo represents very potent inhibition and, insofar as dose levels II and III completely blocked response to this challenge dose, we can conservatively conclude that these doses of eritoran tetrasodium are likely to provide sufficient plasma levels to block endotoxin response in nearly all septic patients, assuming pharmacokinetic parameters of eritoran tetrasodium, such as C max and clearance, are similar to normal volunteers.
The use of TNF-α for this assay provides us with a convenient 'read-out' for response of blood to endotoxin using a relatively robust response generated over a short time period. However, it should be noted that eritoran tetrasodium has been shown to block the generation of all cytokines measured (IL-6, IL-8, IL-10, etc.) when studied in vitro in incubations of human whole blood. 4 All doses of eritoran tetrasodium blocked response to the low-dose of LPS (0.05 ng/ml), and response to lowdose LPS (0.05 ng/ml) was completely blocked for > 22 h after dosing of all dose levels.
Dose level II (plasma levels of~3000 ng/ml eritoran tetrasodium) was found to be sufficient to block response to 1 ng/ml LPS, a level of LPS that has been observed during severe sepsis. 17 However, as discussed above, this measured level may represent an extreme, as circulating LPS is a mixture of active and inactivated molecules that accumulate in lipoproteins over time.
Duration of action following discontinuation of dosing is a function of eritoran tetrasodium dose and the amount of LPS used as challenge. Response to low-dose LPS (0.05 ng/ml) was completely blocked for > 22 h post dosing of all dose levels. When more LPS (1 ng/ml) was used as challenge, dose level I (C ss = 0. 99 µg/ml) was ineffective after ending dosing while both dose levels II and III (C ss =2.6 µg/ml) completely blocked response for > 22 h after ending dosing. Inhibition of 10 ng/ml LPS was incomplete immediately after ending treatment of any dose level of eritoran tetrasodium. Because the pharmacokinetics/pharmacodynamics were similar in males and females ( Fig. 7) , it might be expected that higher plasma concentrations would result in extended pharmacodynamic activity (after discontinuing dosing) in females compared to males. As described in Table 5 , there was a slight increase in the time period of complete inhibition in the dose level III females using a 1 ng/ml LPS challenge dose, but this trend was not apparent in other pharmacodynamic assays.
How do these estimates compare to the activity of eritoran tetrasodium against endotoxin administered in vivo? Because the maximum safely-established dose of endotoxin is 4 ng/kg, there is only one data point available for comparison. However, as discussed above, the ex vivo challenge dose of 0.05 ng/ml LPS represents an estimated C max that may be observed during administration of 4 ng/kg endotoxin. Previously published data have shown that 100 µg of eritoran tetrasodium infused over 30 min is the minimum effective dose for ablating the effects of concomitantly-administered 4 ng/kg endotoxin. In addition, the C max of eritoran tetrasodium following this infusion was~40 ng/ml. 12 Compared to the current ex vivo study using 0.05 ng/ml LPS challenge dose, the extrapolated dose for a minimum plasma concentration for completely inhibiting 0.05 ng/ml LPS is about 1 µg/ml (Table 4 ) or about 25 times the minimum effective dose found for in vivo endotoxin challenge during concomitant administration of drug and endotoxin . However, while the ex vivo assay appears to underestimate the in vivo activity of eritoran tetrasodium, it is important to note that the in vivo minimum effective dose was determined with drug freshly infused into subjects, while the extrapolated value for ex vivo activity includes active eritoran tetrasodium as well as drug already inactivated by lipoproteins.
In estimating clinically-relevant dosing for the treatment of severe sepsis, it must be determined how much antagonist is needed to protect against endotoxin in severe sepsis. Based on the results of this study, it is unlikely that the high plasma levels obtained during 72h continuous infusion 9 are necessary for the treatment of endotoxemia associated with severe sepsis and septic shock. In the current study, dose level III (plasma levels of~10 µg/ml eritoran tetrasodium) is likely to provide a PK/PD of eritoran tetrasodium during and after intermittent infusion 393 wide therapeutic excess to block response to 1 ng/ml LPS. The highest level of LPS challenge in this study was 10 ng/ml LPS and likely represents an extreme plasma level. Even so, ex vivo response to this high level of LPS is inhibited by > 95% in blood from treated males and by ≥ 85% in blood from treated females. Blocking this extreme LPS dose indicates a wider therapeutic window for competitive antagonism of more pathophysiologically-relevant concentrations of LPS in severe sepsis.
